HIV

Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults

Retrieved on: 
Tuesday, March 19, 2024
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MSD, Emory University, Antigen, Streptococcus, International Society, HIV, Risk, Global health, Patient, Cohort, Hospital, Merck & Co., Aes, OPA, Epidemiology, Training school (United States), PCV20, Immunoglobulin G, Attenuated vaccine, MRK, Pediatrics, CDC, Vaccination, PPSV23, Community-acquired pneumonia, Food, FDA, PDUFA, Medicine, Vaccine

V116 also elicited higher immune responses than the studied comparators for the serotypes unique to V116 in all STRIDE studies presented at the meeting.

Key Points: 
  • V116 also elicited higher immune responses than the studied comparators for the serotypes unique to V116 in all STRIDE studies presented at the meeting.
  • If approved, V116 would be the first pneumococcal conjugate vaccine specifically designed for adults.
  • Participants were enrolled based on previous pneumococcal vaccination with PPSV23, PCV15, PCV13 (pneumococcal 13-valent conjugate vaccine), PPSV23+PCV13, PCV13+PPSV23 or PCV15+PPSV23, and received either V116, PCV15 or PPSV23.
  • V116 elicited comparable immune responses to the comparator, PCV15+PPSV23, for all 13 shared serotypes and higher immune responses for the eight serotypes covered only by V116.

Aegis Life Receives Investment to Continue Development of DNA-Encoded Therapeutic Antibodies Against Infectious Diseases Using the Fusogenix PLV Platform

Retrieved on: 
Tuesday, March 19, 2024
Research, Infectious Diseases, Genetics, Biotechnology, AIDS, Health, Pharmaceutical, Other Science, Science, Cell, Bill, HIV, Patient, Viral, Mortality, PLV, Infection, Malaria, Antibody, Therapy, Multimedia, Vaccine

View the full release here: https://www.businesswire.com/news/home/20240319141319/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240319141319/en/
    Aegis will receive up to $4.45 million in funding through a convertible promissory note from the foundation’s Strategic Investment Fund for the purpose of developing DNA-based encoded neutralizing antibody therapies for infectious diseases using the Entos Fusogenix PLV platform.
  • This investment follows an initial grant from the foundation to Aegis made in June 2023 to support this collaborative development project with a focus on HIV and malaria.
  • To address this, Aegis and Entos are developing DNA-encoded antibodies using the Fusogenix PLV platform that can be administered through intramuscular injection.
  • The Fusogenix PLV is fridge-stable and can be manufactured at scale cost-effectively, making it accessible for those living in rural, remote, or infrastructure-poor regions.

‘Ask Viamo Anything’ Combines AI with Basic Mobile Calls to Bring Next Billion Online

Retrieved on: 
Friday, March 15, 2024
Technology, Mobile, Wireless, Social Media, Other Education, Professional Services, Artificial Intelligence, Telecommunications, Education, Agriculture, Communications, Internet, Socially Responsible Investing, Natural Resources, VoIP, Depression, Health, Siri, Smartphone, Sanitation, Human, Woman, Alexa, Intelligence, HIV, Male, Religion, Ageing, Unilever, UNICEF, AI, Organizational founder, Lawyer, Information services, Norm (mathematics), Water, Hygiene, ChatGPT, Snow, Renewable energy

By bringing the latest iteration of AI to some of the world’s poorest and most remote communities, ‘Ask Viamo Anything’ heralds the fastest democratisation of technology to date.

Key Points: 
  • By bringing the latest iteration of AI to some of the world’s poorest and most remote communities, ‘Ask Viamo Anything’ heralds the fastest democratisation of technology to date.
  • “Generative AI shouldn’t just help lawyers in LA do their job 10% better,” says David McAfee, the CEO and Cofounder of platform provider Viamo.
  • By using basic voice calls as the interface, the Viamo platform is accessible to more people than can currently log onto Facebook, Instagram or TikTok.
  • “Combining AI and mobile is the necessary solution to bring the next billion people online,” says McAfee.

AHF Urges Trinidad and Tobago to Sidestep Greedy GSK

Retrieved on: 
Friday, March 15, 2024
AIDS, Public Policy, Government, Health, Infectious Diseases, Advocacy Group Opinion, Pharmaceutical, ARV, GSK, HIV, COVID-19, AHF, Caribbean region of Colombia, Letter, AIDS Healthcare Foundation, Face, Biosimilar, Pharmaceutical industry

AIDS Healthcare Foundation (AHF) is calling on the government of Trinidad and Tobago to consider issuing a compulsory license for Tivicay (dolutegravir), a GSK antiretroviral (ARV) drug that treats HIV, which currently costs 25 times more than available biosimilar generics in neighboring Caribbean countries.

Key Points: 
  • AIDS Healthcare Foundation (AHF) is calling on the government of Trinidad and Tobago to consider issuing a compulsory license for Tivicay (dolutegravir), a GSK antiretroviral (ARV) drug that treats HIV, which currently costs 25 times more than available biosimilar generics in neighboring Caribbean countries.
  • In February, AHF and the Medical Research Foundation of Trinidad & Tobago sent a letter to GSK CEO Dame Emma Walmsley, which in part stated, “We urge you to address the lack of access to the antiretroviral drug Tivicay in Trinidad due to its high cost by lowering its price in line with biosimilar generics available in the Caribbean Region – or by committing not to threaten legal action against the purchase of a generic version of Tivicay.”
    To date, GSK has yet to respond to the letter.
  • Currently, Tivicay is under patent protection in Trinidad and Tobago, and GSK has threatened legal action if the country decides to import affordable generic ARVs.
  • “As a small island nation, Trinidad and Tobago is still recovering from the economic and social consequences of COVID-19 – paying 25 times more to provide lifelong HIV treatment for its people is untenable,” said AHF President Michael Weinstein.

Protesters Keep Heat on Greedy Gilead over Price Gouging

Retrieved on: 
Wednesday, March 13, 2024
Men, General Health, Pharmaceutical, Consumer, State, Local, Infectious Diseases, Public Policy, Health Insurance, Women, AIDS, Health, Government, HIV/AIDS, Conference, AIDS Healthcare Foundation, HIV, Gilead Sciences, AHF, Multimedia, Pharmacy, Pharmaceutical industry

HIV/AIDS advocates from AIDS Healthcare Foundation (AHF) will continue their campaign of protests targeting Gilead Sciences over the company’s ongoing efforts to rack up exorbitant profits while restricting access to its lifesaving medications.

Key Points: 
  • HIV/AIDS advocates from AIDS Healthcare Foundation (AHF) will continue their campaign of protests targeting Gilead Sciences over the company’s ongoing efforts to rack up exorbitant profits while restricting access to its lifesaving medications.
  • Protesters will gather Wednesday in front of the Loews Miami Beach Hotel where executives from Gilead will be presenting at the Barclays Annual Global Health Conference.
  • View the full release here: https://www.businesswire.com/news/home/20240312694416/en/
    The group hosted a similar protest rally targeting Gilead at the Fontainebleau Miami Beach Hotel Tuesday while company executives presented during the Leerink Partners Biopharma Conference.
  • HIV/AIDS activists are also specifically targeting Gilead CEO Daniel O’Day over his February appointment as board chair for PhRMA (Pharmaceutical Research and Manufacturers of America), the cutthroat trade group representing companies in the pharmaceutical industry in the United States.

AHF Keeps Pressure on ‘Greedy Gilead’ Over Price Gouging

Retrieved on: 
Monday, March 11, 2024
Pharmaceutical, Philanthropy, Infectious Diseases, Healthcare Reform, Social Activism, Public Policy, Advocacy Group Opinion, Foundation, Communications, AIDS, Health, Government, HIV/AIDS, Conference, AIDS Healthcare Foundation, HIV, Gilead Sciences, City, AHF, Pharmacy, Pharmaceutical industry

AIDS Healthcare Foundation (AHF) advocates will rally at the Fontainebleau Miami Beach Hotel Tuesday to protest Gilead Sciences ’ ongoing efforts to rack up exorbitant profits while restricting access to lifesaving medications.

Key Points: 
  • AIDS Healthcare Foundation (AHF) advocates will rally at the Fontainebleau Miami Beach Hotel Tuesday to protest Gilead Sciences ’ ongoing efforts to rack up exorbitant profits while restricting access to lifesaving medications.
  • AHF’s sustained protests against the drug maker continue as Gilead faces legal action over its keeping safer HIV medications off the market to maximize profits.
  • “It is so sadly apropos that Gilead CEO Daniel O’Day — the poster child for PhRMA greed — also now sits atop PhRMA, the undisputed fortress of greed,” said Michael Weinstein, AHF president and cofounder.
  • Since 2021, AHF has been taking on Gilead and CEO Daniel O’Day, holding more than two dozen protests in multiple cities, including Washington, DC, Miami, Boston, and Foster City, CA at Gilead’s corporate headquarters.

RSNA: Early Coronary Disease, Impaired Heart Function Found in Asymptomatic People with HIV

Retrieved on: 
Thursday, April 4, 2024
Biomedicine, Cardiovascular disease, MRI, Coronary artery disease, HIV, Didanosine, Viral load, Education, Patient, Facial muscles, Research, Kidney, University, Death, Physical examination, NIH, Society, Life expectancy, Risk, Moyamoya disease, OAK, World Health Organization, RSNA, DRS, Heart, Radiation, Bangladesh Technical Education Board, Digestive, Synthetic control method, Health, Person, Pharmaceutical industry

OAK BROOK, Ill., April 4, 2024 /PRNewswire-PRWeb/ -- A new study found increased coronary vessel wall thickness that was significantly associated with impaired diastolic function in asymptomatic, middle-aged individuals living with HIV. The study was published today in Radiology: Cardiothoracic Imaging, a journal of the Radiological Society of North America (RSNA).

Key Points: 
  • A new study found increased coronary vessel wall thickness that was significantly associated with impaired diastolic function in asymptomatic, middle-aged individuals living with HIV.
  • The ability to detect early coronary artery disease in persons living with HIV and potentially prevent detrimental effects on the heart muscle is important.
  • This research shows the impact of HIV on developing subtle subclinical coronary artery disease and its effects on heart function.
  • "This research shows the impact of HIV on developing subtle subclinical coronary artery disease and its effects on heart function."

Cepheid Announces World Health Organization Prequalification of Xpert HIV-1 Qualitative Test

Retrieved on: 
Wednesday, April 3, 2024
ART, Diagnosis, Mother, Survival, EVP, Cepheid (company), HIV, Viral load, Seroconversion, Cepheid variable, Hospital, Anxiety, Laboratory, Science, World Health Organization, Safety, WHO, Vaccine

SUNNYVALE, Calif., April 3, 2024 /PRNewswire/ -- Cepheid today announced that Xpert® HIV-1 Qual XC has been awarded World Health Organization (WHO) prequalification. Inclusion on the prequalification list signifies that Xpert HIV-1 Qual XC meets WHO's stringent performance, quality, safety and reliability standards. Xpert HIV-1 Qual XC (extended coverage) is an in vitro nucleic acid amplification test for the qualitative detection of HIV-1 total nucleic acids directly from human dried blood spots and capillary or venous whole blood specimens.

Key Points: 
  • SUNNYVALE, Calif., April 3, 2024 /PRNewswire/ -- Cepheid today announced that Xpert® HIV-1 Qual XC has been awarded World Health Organization (WHO) prequalification.
  • Inclusion on the prequalification list signifies that Xpert HIV-1 Qual XC meets WHO's stringent performance, quality, safety and reliability standards.
  • The test has been cleared for use in early diagnosis of infants, adolescents, and adults at the point of care and in laboratories.
  • Xpert HIV-1 Qual XC is part of a comprehensive portfolio of WHO pre-qualified Xpert tests available internationally, including Xpert HIV-1 Viral Load, Xpert HBV Viral load, Xpert HCV Viral Load, Xpert HCV VL Fingerstick, and Xpert HPV, and WHO endorsed Xpert MTB/RIF Ultra and Xpert MTB/XDR.

Viewpoint Educational Program Partners with Hyder Property Management Professionals to Spotlight the Importance of Affordable Housing in the US

Retrieved on: 
Tuesday, April 2, 2024
Professional, Disability studies, Veteran, Lifting, Partnership, HIV, Knowledge, Quality of life, Housing, Conditional sentence, Property management

MIAMI, April 2, 2024 /PRNewswire-PRWeb/ -- Viewpoint, the esteemed educational program hosted by renowned actor Dennis Quaid, is pleased to announce a strategic collaboration with Hyder Property Management Professionals for an upcoming episode dedicated to addressing the critical need for affordable housing in the United States. Filming is set to commence in late April in the picturesque Coachella Valley in California, where the episode will shed light on Hyder's expertise in the sector and their unwavering commitment to fostering equitable housing solutions for families across California. It will also delve into their partnership with the Coachella Valley Housing Coalition and their combined efforts to increase the quantity and quality of affordable housing throughout Southern California.

Key Points: 
  • It will also delve into their partnership with the Coachella Valley Housing Coalition and their combined efforts to increase the quantity and quality of affordable housing throughout Southern California.
  • From innovative financing models to community development strategies, Hyder will showcase its comprehensive approach to addressing the housing needs of underserved populations.
  • Through its partnership with Hyder Property Management Professionals, the program endeavors to explore innovative approaches and sustainable strategies aimed at addressing the housing crisis and ensuring access to safe, decent, and affordable housing for all.
  • Viewers are encouraged to tune in to watch this enlightening episode featuring Hyder Property Management Professionals, hosted by Dennis Quaid.

The Journey Venture Studio Announces Strategic Collaboration with Valleywise Health and Additional Board Members

Retrieved on: 
Thursday, March 28, 2024
Hospital, Aircraft, Community, Burn, Organization, Journey, HIV, Health, Education, Patient, The Journey, Research, History, Trauma, Entrepreneurship, AI, Burn center, Leg, American College, Valleywise Health, Merative, Ecosystem, Safety, PayPal, Multimedia, Social change, Nursing

PHOENIX, March 28, 2024 /PRNewswire-PRWeb/ -- The Journey Venture Studio announced today a strategic collaboration with Valleywise Health, a comprehensive healthcare system with locations throughout the Phoenix metro area. In pursuit of fostering innovation, this collaboration is set to provide diverse entrepreneurs with invaluable access to clinical expertise, patient populations, and community health data to launch successful healthcare startups and create impactful healthcare solutions.

Key Points: 
  • PHOENIX, March 28, 2024 /PRNewswire-PRWeb/ -- The Journey Venture Studio announced today a strategic collaboration with Valleywise Health, a comprehensive healthcare system with locations throughout the Phoenix metro area.
  • They are governed by a publicly elected board of directors focused on exceptional care for all who turn to Valleywise Health.
  • "Partnering with The Journey will help Valleywise Health realize its vision to be nationally recognized for transforming care to improve community health.
  • The strategic collaboration between The Journey and Valleywise Health allows both organizations to pursue unique funding opportunities.